AN OPEN-LABEL PHASE 2 STUDY OF 2 DOSES OF THE HYPOXIA-INDUCIBLE FACTOR (HIF)-2 INHIBITOR BELZUTIFAN FOR THE TREATMENT OF ADVANCED CLEAR CELL RENAL CELL CARCINOMA AFTER PROGRESSION ON SYSTEMIC THERAPY
JOURNAL FOR IMMUNOTHERAPY OF CANCER（2021）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined